Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer

Share :
Published: 28 Sep 2014
Views: 2997
Rating:
Save
Dr Sandra Swain - Washington Cancer Institute, Washington, USA

At a press conference at ESMO 2014, Dr Swain presents the findings of the phase 3 'CLEOPATRA' study which found that patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy compared to those treated with trastuzumab and chemotherapy alone.

Read the news story and watch the interview for more.